Bioverativ (NASDAQ:BIVV) announced its quarterly earnings data on Tuesday. The biotechnology company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.73, Bloomberg Earnings reports. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%.
Shares of Bioverativ (NASDAQ:BIVV) traded up $0.10 during mid-day trading on Tuesday, reaching $103.70. The company had a trading volume of 2,594,494 shares, compared to its average volume of 3,296,336. The firm has a market cap of $11,230.00 and a price-to-earnings ratio of 25.37. Bioverativ has a twelve month low of $43.52 and a twelve month high of $104.30.
Several brokerages have recently weighed in on BIVV. Morgan Stanley raised Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Jefferies Group lowered Bioverativ from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies lowered Bioverativ from an “overweight” rating to a “neutral” rating in a report on Monday, January 22nd. Raymond James Financial lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $63.15.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/bioverativ-bivv-releases-quarterly-earnings-results-beats-expectations-by-0-73-eps.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.